CTLA4 and neoplasm: The landmark discovery of the cytotoxic T lymphocyte-associated protein 4 (CTLA-4/B7-1) and programmed cell death ligand-1/programmed cell death protein-1 (PD-L1/PD-1) interactions are pivotal advancements in tumor immunotherapy, propelling extensive research endeavors into immune checkpoints.